Key Differences Between Aldactone (Spironolactone) and Chlorthalidone
Aldactone (spironolactone) is a potassium-sparing mineralocorticoid receptor antagonist (MRA) that blocks aldosterone receptors in the distal tubule, while chlorthalidone is a thiazide-type diuretic that acts more proximally in the renal tubule and causes potassium loss.
Mechanism of Action
Spironolactone works by competitively binding aldosterone receptors at the aldosterone-dependent sodium-potassium exchange site in the distal convoluted renal tubule 1. This causes sodium and water excretion while retaining potassium 1. It acts as both a diuretic and antihypertensive through this aldosterone antagonism 1.
Chlorthalidone is a monosulfamyl diuretic with a double-ring chemical structure that differs from traditional thiazides 2. It acts more proximally in the renal tubule and causes potassium loss, requiring monitoring for hypokalemia 3.
Clinical Pharmacology
Spironolactone 1:
- Half-life: 1.4 hours (parent drug); active metabolites 13.8-16.5 hours
- Peak concentration: 2.6 hours (parent), 4.3 hours (canrenone metabolite)
- Protein binding: >90%
- Food effect: Increases bioavailability by ~95%
- Dosing: 25-400 mg once daily (typically 50-100 mg for hypertension) 4
Chlorthalidone 2:
- Longer duration of action than spironolactone
- Greater potency than hydrochlorothiazide 3
- Dosing: 12.5-50 mg once daily
Side Effect Profiles
Spironolactone 1:
- Hyperkalemia (more common, especially with renal impairment)
- Gynecomastia and erectile dysfunction in men
- Breast tenderness
- Menstrual irregularities
- Lower risk of metabolic disturbances
Chlorthalidone 5:
- Hypokalemia (requires monitoring)
- Sympathetic nervous system activation 6, 7
- Insulin resistance and metabolic abnormalities 6, 8, 7
- Hyperglycemia
- Hyperuricemia
- Orthostatic hypotension
- Endothelial dysfunction 8
- Reversible increases in serum creatinine 5
Clinical Context and Selection
When to Choose Spironolactone:
Primary aldosteronism: Spironolactone is the medical treatment of choice for bilateral primary aldosteronism at 50-100 mg daily, titrated up to 300-400 mg if needed 4.
Heart failure with preserved ejection fraction: Spironolactone reduces cardiovascular death and heart failure hospitalization 9. Even low doses (15-22.5 mg/day) show efficacy when target doses cannot be tolerated 9.
Resistant hypertension in patients with normal-to-moderate renal function: Spironolactone is preferred when potassium can be safely monitored.
When metabolic preservation is important: Spironolactone does not cause insulin resistance or sympathetic activation, unlike chlorthalidone 6, 8, 7.
When to Choose Chlorthalidone:
Advanced CKD (stage 4) with resistant hypertension: The CLICK trial demonstrated a 13.9 mmHg reduction in 24-hour systolic BP in patients with stage 4 CKD and resistant hypertension 5. Chlorthalidone also reduced albuminuria by 54% 5.
When hyperkalemia risk is prohibitive: Chlorthalidone causes potassium loss rather than retention, making it safer in advanced renal disease where spironolactone carries significant hyperkalemia risk 3, 4.
Initial hypertension treatment: Both 2025 AHA/ACC and 2024 ESC guidelines recognize chlorthalidone as a first-line thiazide-type diuretic option 3, 4.
Critical Safety Considerations
Spironolactone:
- Monitor potassium closely in renal impairment (increased hyperkalemia risk) 1
- Withdraw 4 weeks before aldosterone testing 3
- Start with lowest dose in cirrhosis and titrate slowly 1
- Discontinuation in heart failure patients increases event risk 2-4 fold 9
Chlorthalidone:
- Monitor for hypokalemia, hyperglycemia, and hyperuricemia 5
- Causes persistent sympathetic activation independent of potassium levels 6, 7
- Higher discontinuation rates in elderly and those with renal dysfunction 5
- Use caution when combined with loop diuretics (80% of resistant hypertension patients in CLICK were on loops) 5
Combination Therapy Advantage
Adding spironolactone to chlorthalidone prevents chlorthalidone-induced sympathetic activation and insulin resistance while maintaining BP reduction 6. This combination may be superior to chlorthalidone monotherapy in hypertensive patients requiring thiazide therapy 6.
In acute heart failure with preserved ejection fraction, chlorthalidone showed greater short-term natriuresis than spironolactone at 24 hours 10, but for chronic management, spironolactone preserves endothelial function better 8.
Bottom Line Algorithm
For resistant hypertension with eGFR >30 mL/min: Choose spironolactone (avoids metabolic complications and sympathetic activation).
For resistant hypertension with stage 4 CKD (eGFR 15-30): Choose chlorthalidone 12.5 mg daily (proven efficacy in CLICK trial, lower hyperkalemia risk).
For primary aldosteronism: Spironolactone is the definitive medical therapy.
For metabolically fragile patients (diabetes, metabolic syndrome): Spironolactone avoids insulin resistance.
When both drugs are needed: The combination prevents chlorthalidone's adverse metabolic and sympathetic effects 6.